1Y Close · As of Aug 26, 2026
KANGSTEM BIOTECH operates in the Pharmaceuticals sector.
Legal name: KANGSTEM BIOTECH CO., LTD.
In fiscal year 2025, KANGSTEM BIOTECH (217730) reported revenue of 3.6 billion KRW, down 53.9% from 7.7 billion KRW a year earlier.
Operating profit was -17.7 billion KRW and net income was -10.5 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 220.6 billion KRW, with a P/B of 3.19.
These figures can be verified in the DART filing (receipt no. 20260320001396).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 3.6B | -17.7B | -10.5B |
| 2024 | 7.7B | -14.8B | -8.0B |
| 2023 | 12.7B | -22.8B | -23.2B |
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-13 | Semi-Annual Report (2026.06) |